Syngene International Ltd (SYNGENE) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Syngene achieved solid Q4 results, exceeding INR 1,000 crores in quarterly operating revenue for the first time.
- Reported revenue from operations reached INR 1,018 crores, marking an 11% year-on-year and 8% sequential increase.
- Operating EBITDA grew by 8% year-on-year and 21% sequentially, reaching INR 344 crores with a 34% margin.
- Acquisition of a biologics manufacturing facility in the U.S. significantly expands Syngene's large molecule capabilities.
- Full-year FY25 revenue growth of 4% aligns with guidance, demonstrating resilience in a challenging market.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.